Oladimeji Akinboro

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima et al. · Journal of Clinical Oncology · 2022 · 77 citations

Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.

Erica C. Nakajima, Yi Ren, Jonathon Vallejo et al. · Journal of Clinical Oncology · 2022 · 54 citations

Advanced Nsclc, Pd-l1 Expression, Medicine +15

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Vallejo, Pallavi S. Mishra‐Kalyani et al. · Journal of Clinical Oncology · 2021 · 48 citations

Pd-l1-positive Nsclc, Advanced Nsclc, Chemotherapy Versus Immunotherapy +13

US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer

Oladimeji Akinboro, Nicole Drezner, Anup Amatya et al. · Journal of Clinical Oncology · 2023 · 37 citations · Full text

Electronic Cigarette Use among Survivors of Smoking-Related Cancers in the United States

Oladimeji Akinboro, Stanley Madu Nwabudike, Rawad Elias et al. · Cancer Epidemiology Biomarkers & Prevention · 2019 · 16 citations · Full text